Paper Details

  1. Home
  2. Paper Details

Schizophrenia, antipsychotic drugs, and cardiovascular disease.

Author: GlassmanAlexander H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the growing concern about the cardiovascular risks associated with antipsychotic drugs. The article focuses on the potential for atypical antipsychotics to prolong the QT interval, potentially leading to torsades de pointes and sudden death. While atypical antipsychotics may increase the QT interval, current evidence suggests they do not cause torsades de pointes. However, the article highlights the need to monitor cardiovascular health in psychiatric patients treated with these drugs.
Paper Details　
Original Abstract of the Article :
Since the early 1980s, concern within the psychiatric community about whether antipsychotics are associated with adverse cardiovascular events has grown. In the early 1990s, it became clear that mesoridazine could cause torsades de pointes. More recently, concern has focused on the propensity that s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/16107178

データ提供：米国国立医学図書館（NLM）

Schizophrenia, Antipsychotic Drugs, and Cardiovascular Disease

This study delves into the complex relationship between schizophrenia, antipsychotic medications, and cardiovascular disease. The researchers reviewed the existing literature on the potential cardiovascular risks associated with antipsychotic medications, particularly the atypical antipsychotics. The findings suggest that while some atypical antipsychotics may prolong the QT interval on an electrocardiogram (ECG), this prolongation does not appear to be associated with an increased risk of torsades de pointes (a potentially life-threatening heart rhythm disturbance).

Antipsychotics and Cardiovascular Risk

The review found that while some atypical antipsychotics can prolong the QT interval, this prolongation does not necessarily indicate an increased risk of torsades de pointes. The study also highlighted the importance of being aware of the general cardiovascular risks associated with antipsychotic medications and carefully monitoring patients for potential adverse effects.

Schizophrenia Treatment and Cardiovascular Health

The study underscores the importance of understanding the potential cardiovascular risks associated with antipsychotic medications. Healthcare providers should carefully assess patients' cardiovascular risk factors and monitor them closely for any potential adverse effects, especially when starting or adjusting antipsychotic medications.

Dr.Camel's Conclusion

Imagine a camel caravan navigating a desert landscape, where the heat and exertion can put strain on the camels' hearts. Antipsychotic medications can be like powerful tools that help manage the challenges of schizophrenia, but they may also have side effects that can affect the camels' cardiovascular health. This research reminds us that careful monitoring and consideration of potential risks are crucial when using these medications, ensuring the caravan can continue its journey safely and effectively.
Date :
  1. Date Completed 2005-10-27
  2. Date Revised 2006-11-15
Further Info :

Pubmed ID

16107178

DOI: Digital Object Identifier

16107178

Related Literature

Article Analysis
・Effects of mesoridazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.